Grant

EMBER-4: A Randomized, Open-Label, Phase 3 Study of Adjuvant Imlunestrant Vs Standard Adjuvant Endocrine Therapy in Patients Who Have Previously Received 2 to 5 Years of Adjuvant Endocrine Therapy for

Active

$345.7K Funding

1 People

External

Related Topics

breast cancer, adjuvant therapy, immunotherapy, clinical trial, hormone receptor

People

Octavio Castanos
(CD)
Cancer Center Division﹒Research Compliance Administrator II